OptimizeRx Corporation (OPRX)
NASDAQ: OPRX · Real-Time Price · USD
4.910
+0.160 (3.37%)
Dec 20, 2024, 4:00 PM EST - Market closed
OptimizeRx Revenue
OptimizeRx had revenue of $21.31M in the quarter ending September 30, 2024, with 30.48% growth. This brings the company's revenue in the last twelve months to $88.18M, up 40.40% year-over-year. In the year 2023, OptimizeRx had annual revenue of $71.52M with 14.53% growth.
Revenue (ttm)
$88.18M
Revenue Growth
+40.40%
P/S Ratio
1.01
Revenue / Employee
$648,379
Employees
136
Market Cap
90.45M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 71.52M | 9.07M | 14.53% |
Dec 31, 2022 | 62.45M | 1.16M | 1.89% |
Dec 31, 2021 | 61.29M | 17.98M | 41.51% |
Dec 31, 2020 | 43.31M | 18.72M | 76.08% |
Dec 31, 2019 | 24.60M | 3.39M | 15.99% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Harvard Bioscience | 97.73M |
Exagen | 55.75M |
LENSAR | 48.87M |
Coya Therapeutics | 9.55M |
Adagene | 815.75K |
Monogram Technologies | 365.00K |
Zentek | 29.13K |
OPRX News
- 4 weeks ago - OptimizeRx to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 5 weeks ago - OptimizeRx Corporation (OPRX) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 7 weeks ago - OptimizeRx Sets Third Quarter 2024 Conference Call for November 13, 2024 at 4:30 p.m. ET - GlobeNewsWire
- 3 months ago - OptimizeRx Continues to Expand its Strategic Relationship with a Top-Tier Pharma Client via a Multi-Brand, Multi-Solution Investment Commitment with Over $10M In-Year Total Value - GlobeNewsWire
- 3 months ago - OptimizeRx Launches Novel Brand Eligibility Technology, Enabling Dynamic Direct to Consumer Marketing for Healthcare Audiences - GlobeNewsWire
- 4 months ago - OptimizeRx Corporation (OPRX) Q2 2024 Earnings Call Transcript - Seeking Alpha
- 5 months ago - OptimizeRx Sets Second Quarter 2024 Conference Call for August 8, 2024 at 4:30 p.m. ET - GlobeNewsWire
- 5 months ago - OptimizeRx Delivers AI-Guided Privacy-Compliant Platform for Pharmaceutical Brand Marketing Amid Evolving Consumer Privacy Legislation - GlobeNewsWire